Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: IPSEN
Woman and Man Max 99 years
IPSEN PHARMA SAS
Update Il y a 4 ans
PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS WITH MACROADENOMA
To evaluate the efficacy of Lanreotide Autogel 120 mg when used as primary medical treatment in untreated de novo acromegalic patients with macroadenoma, as assessed by evaluating the change in pituit...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
IPSEN PHARMA, S.A
Update Il y a 4 ans
A phase II, unicentre, randomized, double-blind, parallel and placebo-controlled, pilot study to evaluate the efficacy and safety of Somatuline Autogel (60 mg) in patients with active thyroid-associated ophthalmopaty of moderate intensity. Estudio piloto, de fase II, unicéntrico, aleatorizado, a doble ciego, paralelo y controlado con placebo para evaluar la eficacia y seguridad de Somatulina Autogel R (60 mg) en pacientes con oftalmopatía tiroidea activa de intensidad moderada
To evaluate the efficacy and safety of 3 doses of Somatuline Autogel (60 mg) in the control of the infiltration and edema of the muscle and retrobulbar connective tissue and in the retraction and cont...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
IPSEN PHARMA SAS
Update Il y a 4 ans
A PHASE III, MULTICENTRE, DOUBLE BLIND, PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN CHILDREN WITH DYNAMIC EQUINUS FOOT DEFORMITY DUE TO CEREBRAL PALSY
The primary study objective will be to assess the efficacy of Dysport compared to placebo at Week 4 on the mean change from baseline in ankle joint hypertonicity in children with dynamic equinus foot ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
IPSEN
Update Il y a 4 ans
IPSEN 2-55-52030-726 : Essai de phase 3 randomisé, en double aveugle, comparant l’efficacité d’un traitement par lanreotide autogel® à un placebo chez des patients ayant une tumeur endocrine entéropancréatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multi-centre study to assess the effect of deep subcutaneous injections of lanreotide autogel 120mg adm...
Country
France
organs
Pancréas
,
Tumeurs endocrines digestives
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
IPSEN NV
Update Il y a 4 ans
A PHASE II/III, MULTI-CENTRE, PROSPECTIVE, EXPLORATORY, OPEN LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 MG IN THE SYMPTOMATIC TREATMENT OF PATIENTS WITH REFRACTORY DIARRHEA (MEDICAL APPROACH OF REFRACTORY DIARRHEA)
The primary objective of the trial is to assess the effect of lanreotide autogel 120 mg on stool frequency in subjects with refractory diarrhea at day 28 (mean of last 7 days) compared to baseline.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
IPSEN PHARMA SAS
Update Il y a 4 ans
Clinical research in patients with acromegaly for the assessment of test product BIM23B065, that will be given to them as repeated subcutaneous injection
To assess the pharmacodynamics of repeated administration of BIM23B065 in reducing growth hormone (GH) in subjects with acromegaly
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
IPSEN PHARMA, S.A
Update Il y a 4 ans
ENSAYO CLÍNICO DE PRUEBA DE CONCEPTO, MULTICÉNTRICO, PROSPECTIVO, ALEATORIZADO, ABIERTO Y PARALELO, PARA VALORAR LA EFICACIA DE LA BRAQUITERAPIA CON O SIN TRATAMIENTO HORMONAL CON TRIPTORELINA 22,5MG SEMESTRAL EN PACIENTES CON CÁNCER DE PRÓSTATA RECURRENTE PREVIAMENTE TRATADOS CON RADIOTERAPIA
Comparar la eficacia de braquiterapia vs braquiterapia más triptorelina 22,5 mg (una inyección) semestral en pacientes con cáncer de próstata recurrente previamente tratados con radioterapia. La efica...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
IPSEN PHARMA, S.A
Update Il y a 4 ans
A multicentre, randomized, double-blind, parallel and controlled with placebo pilot study to evaluate the efficacy and safety of a single dose of botulinum toxin Type A (Dysport®) associated with rehabilitation treatment, in patients with primary myofascial syndrome of cervical and dorsal localization
Evaluate the efficacy and safety of a single dose of botulinum toxin associated with rehabilitation treatment, on pain control in patients with primary myofascial syndrome of cervical and dorsal local...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
IPSEN
Update Il y a 4 ans
IPSEN 2-54-52030-156 : Essai de phase 3 randomisé, en double aveugle, comparant l’efficacité et la tolérance d’un traitement palliatif par lanréotide à un placebo chez des patients ayant un carcinomatose péritonéale. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Phase III, multicentre, randomised, double-blind, comparative study to assess the efficacy and safety of lanreotide 30 mg versus placebo as a palliative treatment of clinical symptoms associated with ...
Country
France
organs
Estomac
,
Intestin
,
Secondaire du foie (métastase hépatique)
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Man Max 99 years
IPSEN
Update Il y a 4 ans
Randomised, phase III multicenter, open study of lanreotide in non metastatic castration-resistant prostate cancer patients presenting elevated Chromogranin A levels
To assess the efficacy in terms of Progression-free survival (PFS) of the administration of non steroidal anti androgens and LHRH-a (Arm A) versus lanreotide in addition to non steroidal anti androgen...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
Next